• Home
  • Search Results
  • Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells.

Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells.

Oncology letters (2014-04-26)
Kazuhiro Iguchi, Maki Hashimoto, Masafumi Kubota, Shuji Yamashita, Mitsuhiro Nakamura, Shigeyuki Usui, Tadashi Sugiyama, Kazuyuki Hirano
ABSTRACT

Prostate cancer occurs more frequently among older males and such elderly individuals often have chronic underlying disorders for which various drugs are administered for treatment. The levels of prostate-specific antigen (PSA), a widely used prostate cancer marker, are influenced by a number of drugs, such as non-steroidal anti-inflammatory drugs and statins. In the present study, the drugs prescribed to patients on a repeat prescription collected at the pharmacy of the Gifu Pharmaceutical University (Gifu, Japan) were examined for their effects on the levels of PSA expression in prostate cancer LNCaP cells. Among the 14 drugs investigated, betamethasone, an agonist of the glucocorticoid receptor, was found to increase the levels of PSA mRNA expression in the LNCaP cells. This betamethasone-induced expression was mediated, at least in part, through androgen receptor (AR) transcriptional activation. Dexamethasone, a typical agonist of the glucocorticoid receptor, was also found to stimulate the AR transcriptional activity, however, to a lesser extent than betamethasone. Therefore, it would be interesting to examine in future studies whether the serum PSA levels in prostate cancer patients are influenced by betamethasone.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Acetylsalicylic acid, ≥99.0%
Sigma-Aldrich
Aspirin, meets USP testing specifications
Supelco
Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Magnesium oxide, ≥99.99% trace metals basis
Sigma-Aldrich
Magnesium oxide, ACS reagent, 97%
Sigma-Aldrich
Magnesium oxide, nanopowder, ≤50 nm particle size (BET)
Sigma-Aldrich
Allopurinol, xanthine oxidase inhibitor
Sigma-Aldrich
Magnesium oxide, ≥99% trace metals basis, -325 mesh
Supelco
Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Warfarin, analytical standard
Sigma-Aldrich
Magnesium oxide, 99.99% trace metals basis
Sigma-Aldrich
Acetylsalicylic acid, analytical standard
Supelco
Famotidine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Famotidine
Sigma-Aldrich
Magnesium oxide, light, 95%
USP
Aspirin, United States Pharmacopeia (USP) Reference Standard
Supelco
Allopurinol, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Warfarin, PESTANAL®, analytical standard
Sigma-Aldrich
Betamethasone, ≥98%
Sigma-Aldrich
Lansoprazole, ≥98% (TLC), powder
Sigma-Aldrich
Magnesium oxide, tested according to Ph. Eur., heavy
Sigma-Aldrich
Magnesium oxide, (single crystal substrate), ≥99.9% trace metals basis, <100>, L × W × thickness 10 mm × 10 mm × 0.5 mm
Sigma-Aldrich
Magnesium oxide, -10-+50 mesh, 98%
Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Magnesium oxide, puriss. p.a., ACS reagent, ≥97% (calcined substance, KT)
Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Magnesium oxide, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E 530, light, 98.0-100.5% (calc. for dried substance)
Sigma-Aldrich
Magnesium oxide, BioUltra, ≥97.0% (calcined substance, KT)
Supelco
Betamethasone, VETRANAL®, analytical standard
Betamethasone, European Pharmacopoeia (EP) Reference Standard